163 related articles for article (PubMed ID: 37149797)
1. Epstein‒Barr virus-associated cellular immunotherapy.
Zhang Y; Lyu H; Guo R; Cao X; Feng J; Jin X; Lu W; Zhao M
Cytotherapy; 2023 Sep; 25(9):903-912. PubMed ID: 37149797
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy for Epstein-Barr virus-associated cancers in children.
Straathof KC; Bollard CM; Rooney CM; Heslop HE
Oncologist; 2003; 8(1):83-98. PubMed ID: 12604735
[TBL] [Abstract][Full Text] [Related]
3. Establishment of cytotoxic T lymphocytes specific for autologous Epstein-Barr virus in HIV-infected patients: the feasibility study of EBV-specific immunotherapy for patients with EBV-associated lymphoma.
Hansasuta P; Incomserb P; Buranapraditkun S; Bhattarakosol P
J Med Assoc Thai; 2004 Sep; 87 Suppl 2():S146-51. PubMed ID: 16083179
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic reprogramming sensitizes immunologically silent EBV+ lymphomas to virus-directed immunotherapy.
Dalton T; Doubrovina E; Pankov D; Reynolds R; Scholze H; Selvakumar A; Vizconde T; Savalia B; Dyomin V; Weigel C; Oakes CC; Alonso A; Elemento O; Pan H; Phillip JM; O'Reilly RJ; Gewurz BE; Cesarman E; Giulino-Roth L
Blood; 2020 May; 135(21):1870-1881. PubMed ID: 32157281
[TBL] [Abstract][Full Text] [Related]
5. Non-viral
Braun T; Pruene A; Darguzyte M; Vom Stein AF; Nguyen PH; Wagner DL; Kath J; Roig-Merino A; Heuser M; Riehm LL; Schneider A; Awerkiew S; Talbot SR; Bleich A; Figueiredo C; Bornhäuser M; Stripecke R
Front Immunol; 2023; 14():1086433. PubMed ID: 37033919
[TBL] [Abstract][Full Text] [Related]
6. Combination of Epstein-Barr virus nuclear antigen 1, 3 and lytic antigen BZLF1 peptide pools allows fast and efficient stimulation of Epstein-Barr virus-specific T cells for adoptive immunotherapy.
Wang Y; Aïssi-Rothe L; Virion JM; De Carvalho Bittencourt M; Ulas N; Audonnet S; Salmon A; Clement L; Venard V; Jeulin H; Stoltz JF; Decot V; Bensoussan D
Cytotherapy; 2014 Jan; 16(1):122-34. PubMed ID: 24094498
[TBL] [Abstract][Full Text] [Related]
7. Vaccine strategies against Epstein-Barr virus-associated diseases: lessons from studies on cytotoxic T-cell-mediated immune regulation.
Khanna R; Moss DJ; Burrows SR
Immunol Rev; 1999 Aug; 170():49-64. PubMed ID: 10566141
[TBL] [Abstract][Full Text] [Related]
8. Current Trends and Alternative Scenarios in EBV Research.
Minarovits J; Niller HH
Methods Mol Biol; 2017; 1532():1-32. PubMed ID: 27873264
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy for Epstein-Barr virus-associated malignancies.
Long HM; Parsonage G; Fox CP; Lee SP
Drug News Perspect; 2010 May; 23(4):221-8. PubMed ID: 20520851
[TBL] [Abstract][Full Text] [Related]
10. Interplay between the Epigenetic Enzyme Lysine (K)-Specific Demethylase 2B and Epstein-Barr Virus Infection.
Vargas-Ayala RC; Jay A; Manara F; Maroui MA; Hernandez-Vargas H; Diederichs A; Robitaille A; Sirand C; Ceraolo MG; Romero-Medina MC; Cros MP; Cuenin C; Durand G; Le Calvez-Kelm F; Mundo L; Leoncini L; Manet E; Herceg Z; Gruffat H; Accardi R
J Virol; 2019 Jul; 93(13):. PubMed ID: 30996097
[TBL] [Abstract][Full Text] [Related]
11. Treatment options for post-transplant lymphoproliferative disorder and other Epstein-Barr virus-associated malignancies.
Davis JE; Moss DJ
Tissue Antigens; 2004 Apr; 63(4):285-92. PubMed ID: 15009802
[TBL] [Abstract][Full Text] [Related]
12. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients.
Rooney CM; Smith CA; Ng CY; Loftin SK; Sixbey JW; Gan Y; Srivastava DK; Bowman LC; Krance RA; Brenner MK; Heslop HE
Blood; 1998 Sep; 92(5):1549-55. PubMed ID: 9716582
[TBL] [Abstract][Full Text] [Related]
13. Epstein Barr Virus: Development of Vaccines and Immune Cell Therapy for EBV-Associated Diseases.
Cui X; Snapper CM
Front Immunol; 2021; 12():734471. PubMed ID: 34691042
[TBL] [Abstract][Full Text] [Related]
14. Safety of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for patients with refractory EBV-related lymphoma.
Sun Q; Burton R; Reddy V; Lucas KG
Br J Haematol; 2002 Sep; 118(3):799-808. PubMed ID: 12181048
[TBL] [Abstract][Full Text] [Related]
15. Epstein-Barr virus-specific cytotoxic T-cell recognition of transfectants expressing the virus-coded latent membrane protein LMP.
Murray RJ; Wang D; Young LS; Wang F; Rowe M; Kieff E; Rickinson AB
J Virol; 1988 Oct; 62(10):3747-55. PubMed ID: 2843672
[TBL] [Abstract][Full Text] [Related]
16. Epstein-Barr virus-associated lymphoproliferative disorders.
Grywalska E; Markowicz J; Grabarczyk P; Pasiarski M; Roliński J
Postepy Hig Med Dosw (Online); 2013 May; 67():481-90. PubMed ID: 23752600
[TBL] [Abstract][Full Text] [Related]
17. A Mechanism-Based Targeted Screen To Identify Epstein-Barr Virus-Directed Antiviral Agents.
Li X; Akinyemi IA; You JK; Rezaei MA; Li C; McIntosh MT; Del Poeta M; Bhaduri-McIntosh S
J Virol; 2020 Oct; 94(21):. PubMed ID: 32796077
[TBL] [Abstract][Full Text] [Related]
18. Recognition of Epstein-Barr virus-associated gastric carcinoma cells by cytotoxic T lymphocytes induced in vitro with autologous lymphoblastoid cell line and LMP2-derived, HLA-A24-restricted 9-mer peptide.
Okugawa K; Itoh T; Kawashima I; Takesako K; Mazda O; Nukaya I; Yano Y; Yamamoto Y; Yamagishi H; Ueda Y
Oncol Rep; 2004 Oct; 12(4):725-31. PubMed ID: 15375491
[TBL] [Abstract][Full Text] [Related]
19. Rapid generation of EBV-specific cytotoxic T lymphocytes resistant to calcineurin inhibitors for adoptive immunotherapy.
Ricciardelli I; Brewin J; Lugthart G; Albon SJ; Pule M; Amrolia PJ
Am J Transplant; 2013 Dec; 13(12):3244-52. PubMed ID: 24266973
[TBL] [Abstract][Full Text] [Related]
20. MicroRNAs of Epstein-Barr Virus Attenuate T-Cell-Mediated Immune Control
Murer A; Rühl J; Zbinden A; Capaul R; Hammerschmidt W; Chijioke O; Münz C
mBio; 2019 Jan; 10(1):. PubMed ID: 30647153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
